Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function.

NCT02665039 is registered in ClinicalTrials.gov with Dr Anders Ullén as lead sponsor.

NCT NCT02665039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02665039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function.
Lead sponsor
Dr Anders Ullén
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2014
Completion date
September 30, 2018
Enrollment
62 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, renal pelvis cancer, ureter cancer, urethra cancer, urothelial carcinoma